{"filing":{"accession_number":"0001193125-26-281246","cik":"0001534133","ticker":"CALC","company_name":"CalciMedica, Inc.","form":"8-K","filing_date":"2026-06-24","report_date":null,"primary_document":"d142943d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312526281246/d142943d8k.htm"},"events":[{"id":13596,"run_id":12076,"accession_number":"0001193125-26-281246","anchor_item_number":"3.02","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"CalciMedica entered into a securities purchase agreement for a private placement of approximately $49 million in gross proceeds, comprising 18,673,429 units of common stock (or pre-funded warrants), Series A warrants, and Series B warrants. The unregistered securities rely on Section 4(a)(2) exemption and carry restrictive legends, with potential for up to $34 million additional proceeds if warrants are exercised.","company_name":"CalciMedica, Inc.","ticker":"CALC","filing_date":"2026-06-24","form":"8-K","submitted_at":null,"items":[{"id":10777,"accession_number":"0001193125-26-281246","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"CalciMedica entered into a securities purchase agreement for a private placement of 18,673,429 units comprising common stock (or pre-funded warrants) and Series A and B warrants, generating approximately $15 million in upfront gross proceeds with potential for up to $34 million additional if warrants are exercised. This is a classic dilutive equity issuance to institutional and accredited investors, including insiders, disclosed under Item 1.01 as a material definitive agreement. The unregistered sale of equity securities in a private placement is a hallmark dilutive issuance event material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-24T21:03:59.794427+00:00","company_name":"","ticker":null,"filing_date":""},{"id":10778,"accession_number":"0001193125-26-281246","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Item 3.02 discloses an unregistered private placement of approximately $49 million in gross proceeds, comprising 18,673,429 units with common stock (or pre-funded warrants), Series A warrants, and Series B warrants. The filing explicitly states the securities \"have not been registered under the Securities Act of 1933\" and relies on Section 4(a)(2) exemption, with restrictive legends affixed. This is a classic dilutive equity issuance by a clinical-stage biopharmaceutical company raising capital, material to investors assessing ownership dilution and the company's financial runway.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-24T21:03:59.794427+00:00","company_name":"","ticker":null,"filing_date":""},{"id":10779,"accession_number":"0001193125-26-281246","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"CalciMedica announced entry into a definitive securities purchase agreement for a private placement of approximately $49 million in gross proceeds, comprising common stock, pre-funded warrants, and Series A and B warrants. The filing explicitly states the Company \"has entered into the Purchase Agreement\" and describes the unregistered sale of 18,673,429 units with multiple warrant tranches. This is a classic dilutive equity issuance to raise capital, material to investors assessing ownership dilution and the company's capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-24T21:03:59.794427+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":13597,"run_id":12076,"accession_number":"0001193125-26-281246","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"CalciMedica announced a focused pulmonary hypertension strategy using proceeds from the private placement, including a planned Phase 1b proof-of-concept study with Auxora and advancement of CM5480 toward IND clearance. The FDA also cleared the company to continue the KOURAGE trial following review of interim safety data and protocol amendments.","company_name":"CalciMedica, Inc.","ticker":"CALC","filing_date":"2026-06-24","form":"8-K","submitted_at":null,"items":[{"id":10780,"accession_number":"0001193125-26-281246","item_number":"8.01","item_title":"Other Events","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The Item 8.01 disclosure centers on two operational/strategic developments: (1) CalciMedica's announcement of a focused pulmonary hypertension strategy using proceeds from a private placement, including a planned Phase 1b proof-of-concept study with Auxora and advancement of CM5480 toward IND clearance; and (2) FDA clearance to continue the KOURAGE trial following review of interim safety data and protocol amendments. While the private placement itself is a financing event (dilutive_issuance), the Item 8.01 focuses on the strategic use of proceeds and clinical development plans rather than the financing mechanics. The FDA clearance to proceed with clinical development is a regulatory milestone supporting the company's pipeline advancement. These are material operational/strategic milestones for a clinical-stage biotech company, but do not fit neatly into specific categories like earnings_release, exec_appointment, or ma_activity.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-24T21:03:59.794427+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":10777,"accession_number":"0001193125-26-281246","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"CalciMedica entered into a securities purchase agreement for a private placement of 18,673,429 units comprising common stock (or pre-funded warrants) and Series A and B warrants, generating approximately $15 million in upfront gross proceeds with potential for up to $34 million additional if warrants are exercised. This is a classic dilutive equity issuance to institutional and accredited investors, including insiders, disclosed under Item 1.01 as a material definitive agreement. The unregistered sale of equity securities in a private placement is a hallmark dilutive issuance event material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-24T21:03:59.794427+00:00","company_name":"CalciMedica, Inc.","ticker":"CALC","filing_date":"2026-06-24"},{"id":10778,"accession_number":"0001193125-26-281246","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Item 3.02 discloses an unregistered private placement of approximately $49 million in gross proceeds, comprising 18,673,429 units with common stock (or pre-funded warrants), Series A warrants, and Series B warrants. The filing explicitly states the securities \"have not been registered under the Securities Act of 1933\" and relies on Section 4(a)(2) exemption, with restrictive legends affixed. This is a classic dilutive equity issuance by a clinical-stage biopharmaceutical company raising capital, material to investors assessing ownership dilution and the company's financial runway.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-24T21:03:59.794427+00:00","company_name":"CalciMedica, Inc.","ticker":"CALC","filing_date":"2026-06-24"},{"id":10779,"accession_number":"0001193125-26-281246","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"CalciMedica announced entry into a definitive securities purchase agreement for a private placement of approximately $49 million in gross proceeds, comprising common stock, pre-funded warrants, and Series A and B warrants. The filing explicitly states the Company \"has entered into the Purchase Agreement\" and describes the unregistered sale of 18,673,429 units with multiple warrant tranches. This is a classic dilutive equity issuance to raise capital, material to investors assessing ownership dilution and the company's capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-24T21:03:59.794427+00:00","company_name":"CalciMedica, Inc.","ticker":"CALC","filing_date":"2026-06-24"},{"id":10780,"accession_number":"0001193125-26-281246","item_number":"8.01","item_title":"Other Events","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The Item 8.01 disclosure centers on two operational/strategic developments: (1) CalciMedica's announcement of a focused pulmonary hypertension strategy using proceeds from a private placement, including a planned Phase 1b proof-of-concept study with Auxora and advancement of CM5480 toward IND clearance; and (2) FDA clearance to continue the KOURAGE trial following review of interim safety data and protocol amendments. While the private placement itself is a financing event (dilutive_issuance), the Item 8.01 focuses on the strategic use of proceeds and clinical development plans rather than the financing mechanics. The FDA clearance to proceed with clinical development is a regulatory milestone supporting the company's pipeline advancement. These are material operational/strategic milestones for a clinical-stage biotech company, but do not fit neatly into specific categories like earnings_release, exec_appointment, or ma_activity.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-24T21:03:59.794427+00:00","company_name":"CalciMedica, Inc.","ticker":"CALC","filing_date":"2026-06-24"}]}